webtrekker

They call us 'Anti-Vaxxers' and 'Conspiracy Theorists' so I reckon it's time we called them by their true name ...

Anyone watch the 'Goliath' series on Prime? This intro came up in Season 4, very apt! ...

About time too ... SOME REAL WARRIORS OUTSIDE OF DR HILARY JONES’ HOUSE https://www.bitchute.com/video/gAC1XRMFFgt4/

Worth reading the tweet ...

Press release29 June 2021Brussels COVID-19 Therapeutics Strategy: Commission identifies five promising candidate therapeutics * “Vaccination against COVID-19 offers the best way to end the pandemic and get back to a normal life. In parallel, we are working to have the best treatments available for those who are infected.” * The EU Strategy on COVID-19 Therapeutics delivers today its first outcome, with the announcement of the first portfolio of five therapeutics that could soon be available to treat patients across the EU. Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines Agency. Another one is an immunosuppressant, which has a marketing authorisation that could be extended to include the treatment of COVID-19 patients. Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates under development and authorise at least three new therapeutics by the end of the year. This is the European Health Union in action.” The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are: A new COVID-19 indication for existing medicines: baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment Newly developed monoclonal antibodies under rolling review - a regulatory tool to speed up the assessment of a promising medicine during a public health emergency: combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review regdanvimab from Celltrion: under rolling review sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review Next Steps The Commission will draw up a portfolio of at least 10 potential COVID-19 therapeutics by October, building on the work of the newly established expert group on COVID-19 variants. The selection process will be objective and science based, with selection criteria agreed with the Member States. Since different types of products are needed for different patient populations and different stages and severity of the disease, the expert group will identify product categories and select the most promising therapeutics candidates for each category based on science based criteria. The portfolio will contribute to the objective of having at least three new therapeutics authorised by October and possibly two more by the end of the year. The European Medicines Agency will start more rolling reviews of promising therapeutics by end-2021, subject to research and development outcomes. The Commission recently concluded a joint procurement of monoclonal antibodies (casirivimab and imdevimab) and could launch more by the end of the year. The first industry matchmaking event on therapeutics will be organised on the 12-13 July to ensure that once authorised therapeutics are produced in sufficient quantity as soon as possible. Background The EU Strategy on COVID-19 Therapeutics aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use. The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe's health systems. The Strategy, which focuses on the treatment of patients with COVID-19, works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.

Press release29 June 2021Brussels COVID-19 Therapeutics Strategy: Commission identifies five promising candidate therapeutics * “Vaccination against COVID-19 offers the best way to end the pandemic and get back to a normal life. In parallel, we are working to have the best treatments available for those who are infected.” * The EU Strategy on COVID-19 Therapeutics delivers today its first outcome, with the announcement of the first portfolio of five therapeutics that could soon be available to treat patients across the EU. Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines Agency. Another one is an immunosuppressant, which has a marketing authorisation that could be extended to include the treatment of COVID-19 patients. Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates under development and authorise at least three new therapeutics by the end of the year. This is the European Health Union in action.” The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are: A new COVID-19 indication for existing medicines: baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment Newly developed monoclonal antibodies under rolling review - a regulatory tool to speed up the assessment of a promising medicine during a public health emergency: combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review regdanvimab from Celltrion: under rolling review sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review Next Steps The Commission will draw up a portfolio of at least 10 potential COVID-19 therapeutics by October, building on the work of the newly established expert group on COVID-19 variants. The selection process will be objective and science based, with selection criteria agreed with the Member States. Since different types of products are needed for different patient populations and different stages and severity of the disease, the expert group will identify product categories and select the most promising therapeutics candidates for each category based on science based criteria. The portfolio will contribute to the objective of having at least three new therapeutics authorised by October and possibly two more by the end of the year. The European Medicines Agency will start more rolling reviews of promising therapeutics by end-2021, subject to research and development outcomes. The Commission recently concluded a joint procurement of monoclonal antibodies (casirivimab and imdevimab) and could launch more by the end of the year. The first industry matchmaking event on therapeutics will be organised on the 12-13 July to ensure that once authorised therapeutics are produced in sufficient quantity as soon as possible. Background The EU Strategy on COVID-19 Therapeutics aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use. The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe's health systems. The Strategy, which focuses on the treatment of patients with COVID-19, works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.

HEADS UP - The reason behind the booster shots - IMPORTANT NEW INFO! This is well worth listening to ... [CLICK IMAGE FOR VIDEO]

[CLICK IMAGE FOR VIDEO]

Saw this in a comment on the net ... GO (Graphene Oxide) is made of Carbon, 6 neutrons, 6 electrons and 6 protons. 6uild 6ack 6etter folks.

Simone Gold is head of America's Frontline Doctors group. Very knowledgeable.

Pro-Jab Professor’s ‘Quick Death’ After COVID ‘Booster’ Shot Published on September 28, 2021 Written by John O'Sullivan Zealous COVID vaccine promoting professor who attacked anti-vaxxers as “selfish” dies after getting her third jab. In what is fast becoming a pattern of quick deaths after the so-called “booster” shots, Mrs Karen Croake Heisler was notorious for using her Twitter account to attack anti-vaxxers. The former Notre Dame scholar had been a passionate campaigner for endless mask wearing and social distancing. She insisted those who refuse to take the experimental COVID19 gene therapy should be locked in their homes “till they see sense.” Her demise caught the attention of social media followers who suffered her ire. As Jim Crenshaw writes: “This bitch needed to go. Her middle name was “Croake”…she did. Some things just work out. Blamed the unvaccinated for her illness. As I have said, it is not about intelligence level. It is about environment. A college professor. Really. This is what is killing doctors and health care professionals. They are so deeply sold on their own abilities and bullshit they cannot see the truth no matter what. She killed herself and does not know it. Her family I am sure blames the unvaccinated for her death. There is a war brewing with these people.” Video source: www.bitchute.com

If they were going to do this don't you think it would have already started by now? It's just more scare-mongering.

The Spartacus Letter Disappearing everywhere across the internet. You can (at this point in time) download it from Ehden Biber's Telegram site at ... https://t.me/eh_den/131?single Let me know (PM me) if you have any problems and I will send you my copy. PDF is 14 pages long with a following 17 pages of verified references.

Well, all I can say is that anyone gullible enough to pay for expensive water filtration is as crazy as someone paying Big Pharma for worthless medical treatments.

Excerpt from Tapewswire article: To sum up: Fluoride in the water could potentially make future generations of people compliant, gullible and stupid. Or, in other words, it’s the perfect thing to start pumping into the water when you’ve just tried to launch a global coup, and not enough people are falling for it. https://tapnewswire.com/2021/09/uk-to-begin-nation-wide-fluoridation-of-tap-water/

What are the disadvantages (cons) of RO filtration? Wastes as much as 6x the amount of clean water produced Requires professional maintenance to ensure effectiveness and safety Removes healthy minerals including calcium, magnesium, potassium and bicarbonates Relatively expensive starting from $300 + maintenance and replacements Risk of bacteria growing in the water after the filter since the chlorine has been removed Also, the WHO says (if you believe anything they say!): 'Low mineral (TDS) drinking water produced by reverse osmosis or distillation is not suitable for long term human consumption and in fact, can create negative health effects to those consuming it. This lack of minerals may also impact the taste negatively for many people.'

This MURDEROUS FUCKER needs stopping, NOW!

Post from Telegram ...

`Today, children, instead of writing an essay about what you did in your summer holidays, I want you to write a paper on how the nasal flu spray may interact with the experimental mRNA jab, with particular reference to those individuals with compromised immune systems. And then, children, explain how the Government will blame the extra deaths on covid-19. You have twenty minutes to complete your essay.’ https://tapnewswire.com/2021/09/shocking-urgent-news-share-widely/

Yeah, the Taliban got a better deal than us from the US!

Fake! I've been told the proper procedure is to always use BOTH hands, One to inject, the other to line up the target, commonly known as 'landscaping,' I believe.

"No Soul, No Free Will." - The End of Humanity? [CLICK IMAGE FOR VIDEO]